{"id":1641,"date":"2007-05-30T11:19:43","date_gmt":"2007-05-30T10:19:43","guid":{"rendered":"http:\/\/www.ethicalquote.com\/index.php\/2007\/05\/30\/ethical-reputations-of-top-pharma-firms-revealed\/"},"modified":"2007-06-11T09:22:09","modified_gmt":"2007-06-11T08:22:09","slug":"ethical-reputations-of-top-pharma-firms-revealed","status":"publish","type":"post","link":"https:\/\/www.covalence.ch\/index.php\/2007\/05\/30\/ethical-reputations-of-top-pharma-firms-revealed\/","title":{"rendered":"Ethical reputations of top pharma firms revealed"},"content":{"rendered":"<p><font color=\"#333333\" face=\"arial\" size=\"2\">The latest ethical reputations of the world&#8217;s largest pharmaceutical companies have been revealed, with GlaxoSmithKline (GSK) emerging as big pharma&#8217;s Mother Theresa, according to a recently-released compilation by Geneva-based ethical-monitoring firm Covalence<strong>. <\/strong><\/font><span class=\"verdana11000000\">Interestingly, earning power and <a href=\"javascript:KeywordSearch('KEYWORDS=ethical&#038;period=all&#038;inner=1');\" class=\"arial113399cc\">ethical<\/a> nature do not necessarily appear to go hand in hand. Covalence has published its quarterly ethical reputation ranking, highlighting the top 10 highest-ranking pharmaceutical companies, as well as those which have made the most progress in the first quarter of 2007, and the companies who have received the most positive news coverage.<\/span><\/p>\n<p>Publication about Covalence <span class=\"LinkBlueTransMedium\">| Country: Global<\/span><span class=\"LinkBlueTransMedium\"><\/span><span class=\"LinkBlueTransMedium\"> | Company: <\/span><a href=\"http:\/\/www.ethicalquote.com\/newTemplate\/index.php\/ethicalquote\/?value=8\">GlaxoSmithKline<span class=\"LinkBlueTransMedium\">, <\/span>Bristol-Myers Squibb, Johnson &#038; Johnson, <span class=\"verdana11000000\">Pfizer, Merck &#038; Co, <\/span><span class=\"verdana11000000\">AstraZeneca, <\/span><span class=\"verdana11000000\">Novartis, Roche, <\/span><span class=\"verdana11000000\">Abbott, <\/span><span class=\"verdana11000000\">Boehringer Ingelheim<\/span><\/a><span class=\"LinkBlueTransMedium\"> |<\/span><span class=\"LinkBlueTransMedium\"> <\/span><span class=\"LinkBlueTransMedium\"><span class=\"LinkBluePgtMedium\"><\/span><\/span><span class=\"LinkBlueTransMedium\"> <\/span><span class=\"LinkBlueTransMedium\"><\/span>Source: <a href=\"http:\/\/www.biopharma-reporter.com\/news\/ng.asp?n=76941-gsk-ethical-revenue\" target=\"_blank\" class=\"LinkBluePgtMedium\">BioPharma Reporter.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The latest ethical reputations of the world&#8217;s largest pharmaceutical companies have been revealed, with GlaxoSmithKline (GSK) emerging as big pharma&#8217;s Mother Theresa, according to a recently-released compilation by Geneva-based ethical-monitoring firm Covalence. Interestingly, earning power and ethical nature do not necessarily appear to go hand in hand. Covalence has published its quarterly ethical reputation ranking,&hellip;<\/p>\n","protected":false},"author":665,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"wds_primary_category":0,"wds_primary_post_series":0,"footnotes":""},"categories":[2],"tags":[104,102,105,101,62,30,40,11,42,103],"post_series":[],"class_list":["post-1641","post","type-post","status-publish","format-standard","hentry","category-publications","tag-abbott","tag-astrazeneca","tag-boehringer-ingelheim","tag-bristol-myers-squibb","tag-gsk","tag-jj","tag-merck-co","tag-novartis","tag-pfizer","tag-roche","entry","no-media"],"_links":{"self":[{"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/posts\/1641","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/users\/665"}],"replies":[{"embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/comments?post=1641"}],"version-history":[{"count":0,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/posts\/1641\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/media?parent=1641"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/categories?post=1641"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/tags?post=1641"},{"taxonomy":"post_series","embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/post_series?post=1641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}